Find a Trial Find Expert Physicians 
News Trial Stats
Clinical TrialsFacts & Fears Who pays for it, placebos, being a guinea pig, and what taking part really means.Basics ofTheranostics A fundamental way of finding and treating your cancer, all in one.Basics ofRadiation What is radiation, and how can it benefit you? InterpretingYour Scans What CT, MRI and PET can and can’t tell you about cancer.What to Expect as aTheranostic Patient Scans, treatment day, and the precautions once you are home.Basics ofDosimetry How much radiation each organ and tumor actually absorbs.TheranosticDictionary Plain-language meanings for the vocabulary on your paperwork.
News Trial Stats
Contact XCancer®
Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT04833959
Pilot Study of 89-Zr Panitumumab in Pancreas Cancer
Overview
The main purpose of the study is to assess the safety of 89Zr-panitumumab as a molecular imaging agent in patients with (metastatic) pancreas cancer.
Sponsor
Stanford University
Phase
Phase 1
Contacts
Andrei Iagaru (PRINCIPAL_INVESTIGATOR)
ClinicalTrials.gov
NCT04833959Eligibility
Inclusion
- Confirmed diagnosis of pancreatic cancer.
Exclusion
- Known hypersensitivity to deferoxamine or any of its components.
- Pregnant or breastfeeding.
- History of infusion reactions to monoclonal antibody therapies.
- Subjects with a history or evidence of interstitial pneumonitis or pulmonary fibrosis.
- Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); significant liver disease; or unstable angina within 6 months prior to enrollment.
- Severe renal disease or anuria.
- Subjects receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents.
Share your feedback
Help us improve your experience